This study is testing a new type of cell therapy called BAFF CAR-T cells (LMY-920) for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. This therapy uses your own immune cells, called T-cells, which are specially modified to target and fight lymphoma cells. Researchers want to find the safest and most effective dose of LMY-920. This treatment is being explored as another option, especially if previous CAR-T cell therapies targeting CD19 haven't worked. You may be able to join if you have non-Hodgkin lymphoma that has returned after at least two other treatments, or if your disease has not responded to chemotherapy or returned within a year of a stem cell transplant. The study aims to enroll 20 participants.

Study design

This is a Phase 1 study, meaning it's an early-stage study to find a safe dose. It plans to enroll 20 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of the study will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.